NCT00268697 - Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia. | Biotech Hunter

Enrollment

1,267

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions

Hypercholesterolemia

Interventions

DRUG

Lapaquistat acetate

Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.

DRUG

Lapaquistat acetate and ezetimibe

Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.

DRUG

Ezetimibe

Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.

Trial Locations (9)

Tallinn

Tartu

Riga

Moscow

Saint Petersburg

Saratov

Smolensk

Tyumen

Kragujevac